Company news

Share this article:

Drug developer Depomed said it would cut about 25% of its workforce after its lead drug candidate, Gabapentin GR, failed in a late-stage clinical trial. The company had 105 full-time employees as of Dec. 31, according to a filing with the Securities and Exchange Commission.


Forest Laboratories and Microbia announced that they have entered into co-development and co-marketing deal valued at up to $330 million for Microbia's first-in-class compound linaclotide, currently being investigated for the treatment of constipation-predominant irritable bowel syndrome, chronic constipation and other gastrointestinal disorders.

Share this article:
You must be a registered member of MMM to post a comment.

Does a health psychology approach hold the key to Rx adherence? In MM&M's latest Leadership Exchange Uncut eBook, industry stakeholders from the payer, provider, academic and pharma realms explore the "why" behind medicine taking. Access here.